-
Je něco špatně v tomto záznamu ?
Metformin may ameliorate inflammatory events of il-18 in some inflammatory conditions
Ajil A. Alzamily, Karrar M. Obaid, Buthainah Al-Azzawi
Jazyk angličtina Země Česko
Digitální knihovna NLK
Zdroj
NLK
ROAD: Directory of Open Access Scholarly Resources
od 2011
- MeSH
- cytokiny účinky léků MeSH
- diabetes mellitus farmakoterapie MeSH
- interleukin-8 účinky léků MeSH
- klinická studie jako téma MeSH
- lidé MeSH
- metformin * farmakologie terapeutické užití MeSH
- zánět farmakoterapie MeSH
- Check Tag
- lidé MeSH
Background: Interleukin-18 (IL-18) belongs to the cytokine family IL-1. IL-18 is synthesized as inactive precursors which need to be processed into an active interleukin by the Caspase-1 enzyme. The role of IL-18 is implicated in several auto-immune disorders, myocardial function, emphysema, metabolic syndromes, psoriasis, bowel inflammation, sepsis, and acute kidney injury. IL-18 exhibits pro-inflammatory properties, such as increased cell adhesion molecules, nitric oxide production, enhancement of T-cell and natural killer cell maturation, and increasing the production of chemokines. This study was designed from November 2020 to February 2021 at Al-Shomali hospital, Babylon governorate, Iraq. This study aimed to assess the levels of IL-18 in patients with PCOS, T2DM and CAD before treatment with metformin and after metformin medication, and to evaluate the roles of IL-18 in the development of this disease. Materials and methods: The study design is a case-control study and patients are selected by simple randomization after diagnosis by a specialist based on clinical diagnosis and laboratory findings. An enzyme-linked immunosorbent test (ELISA) was used to estimate the level of serum IL-18 before and after metformin administration. A total of 300 patients were involved in this study, divided according to their chronic illness as 60 women with PCOS, 60 patients Type 2 diabetes mellitus (T2DM), 60 patients with myocardial infarction (MI), and 60 patients with T2DM and MI. In addition, 30 healthy people as a control group. Results: Before treatment with metformin, the results were exhibited a significant difference (P≤0.0001) in the concentrations of IL-18 in PCOS, T2DM, and patients with CAD as compared with control. While, after metformin treatment, a significant decrease (P≤0. 01, P≤0.0001 and P≤0.001) in IL-18 level in patients with PCOS and T2DM and CAD respectively as compared to before metformin treatment. Conclusion: Metformin administration reduces the inflammatory events of IL-18 in patients with T2DM and CAD and PCOS.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22021738
- 003
- CZ-PrNML
- 005
- 20221111092850.0
- 007
- ta
- 008
- 220920s2022 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.31482/mmsl.2021.039 $2 doi
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Alzamily, Ajil A. $u University of AL-Qadisiyah; College of Medicine, Iraq
- 245 10
- $a Metformin may ameliorate inflammatory events of il-18 in some inflammatory conditions / $c Ajil A. Alzamily, Karrar M. Obaid, Buthainah Al-Azzawi
- 520 9_
- $a Background: Interleukin-18 (IL-18) belongs to the cytokine family IL-1. IL-18 is synthesized as inactive precursors which need to be processed into an active interleukin by the Caspase-1 enzyme. The role of IL-18 is implicated in several auto-immune disorders, myocardial function, emphysema, metabolic syndromes, psoriasis, bowel inflammation, sepsis, and acute kidney injury. IL-18 exhibits pro-inflammatory properties, such as increased cell adhesion molecules, nitric oxide production, enhancement of T-cell and natural killer cell maturation, and increasing the production of chemokines. This study was designed from November 2020 to February 2021 at Al-Shomali hospital, Babylon governorate, Iraq. This study aimed to assess the levels of IL-18 in patients with PCOS, T2DM and CAD before treatment with metformin and after metformin medication, and to evaluate the roles of IL-18 in the development of this disease. Materials and methods: The study design is a case-control study and patients are selected by simple randomization after diagnosis by a specialist based on clinical diagnosis and laboratory findings. An enzyme-linked immunosorbent test (ELISA) was used to estimate the level of serum IL-18 before and after metformin administration. A total of 300 patients were involved in this study, divided according to their chronic illness as 60 women with PCOS, 60 patients Type 2 diabetes mellitus (T2DM), 60 patients with myocardial infarction (MI), and 60 patients with T2DM and MI. In addition, 30 healthy people as a control group. Results: Before treatment with metformin, the results were exhibited a significant difference (P≤0.0001) in the concentrations of IL-18 in PCOS, T2DM, and patients with CAD as compared with control. While, after metformin treatment, a significant decrease (P≤0. 01, P≤0.0001 and P≤0.001) in IL-18 level in patients with PCOS and T2DM and CAD respectively as compared to before metformin treatment. Conclusion: Metformin administration reduces the inflammatory events of IL-18 in patients with T2DM and CAD and PCOS.
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 17
- $a metformin $x farmakologie $x terapeutické užití $7 D008687 $2 czmesh
- 650 _7
- $a interleukin-8 $x účinky léků $7 D016209 $2 czmesh
- 650 _7
- $a diabetes mellitus $x farmakoterapie $7 D003920 $2 czmesh
- 650 _7
- $a zánět $x farmakoterapie $7 D007249 $2 czmesh
- 650 _7
- $a cytokiny $x účinky léků $7 D016207 $2 czmesh
- 650 _7
- $a klinická studie jako téma $7 D000068456 $2 czmesh
- 700 1_
- $a Obaid, Karrar M. $u Medical Laboratory Department, Al-Shomaliʼs hospital, Babylon, Iraq
- 700 1_
- $a Al-Azzawi, Buthainah $u University of AL-Qadisiyah; College of Medicine, Iraq
- 773 0_
- $t Vojenské zdravotnické listy $x 0372-7025 $g Roč. 91, č. 3 (2022), s. 170-181 $w MED00011116
- 856 41
- $u https://mmsl.cz/artkey/mms-202203-0001_metformin-may-ameliorate-inflammatory-events-of-il-18-in-some-inflammatory-conditions.php $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 3 $c 1073 $y p $z 0
- 990 __
- $a 20220909 $b ABA008
- 991 __
- $a 20221111092842 $b ABA008
- 999 __
- $a ok $b bmc $g 1840083 $s 1173006
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 91 $c 3 $d 170-181 $e 20220902 $i 0372-7025 $m Vojenské zdravotnické listy $x MED00011116
- LZP __
- $c NLK109 $d 20221021 $b NLK111 $a Actavia-MED00011116-20220909